Knee surgery patients may skip hospital stay with anti-nausea drug

NCT ID NCT07639723

Not yet recruiting Symptom relief Sponsor: Endeavor Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the nausea drug aprepitant to standard care helps more people having knee replacement surgery go home the same day. About 350 adults will receive either aprepitant plus usual anti-nausea medicines or a placebo plus usual care. The goal is to see if better nausea control reduces the need for an overnight hospital stay.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aprepitant
What this could lead to: If it works, this could help more knee replacement patients avoid an overnight hospital stay by better controlling nausea and vomiting.
What could go wrong: This is a Phase 4 trial, but it has not started recruiting yet. The benefit may be small, and some patients may still need to stay overnight for other reasons.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PONV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Postoperative Nausea and Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PONV

Contacts and locations

Locations

Endeavor Health Skokie Hospital

Skokie, Illinois, 60076, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.